CompletedNCT00488319
Extended-release paliperidone for adolescents with schizophrenia
About this title
Read the official source — NCT00488319Researchers studied Paliperidone ER, tracking side effects to assess safety and tolerability in young people with schizophrenia.
Medication studyAges 12–17Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Paliperidone ER, tracking side effects to assess safety and tolerability in young people with schizophrenia.
Who was this study for?
Listed age limits: 12 years to 17 years.
- Listed locations
- Cerritos and 52 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 400
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Belgium, Bulgaria, ...
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT00488319
- Official title
Show the full official title
A 6-Month, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5 - 12 mg/Day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cerritos, United States · San Diego, United States · Santa Ana, United States
51 more locations
- Middletown, United States
- Washington D.C., United States
- Jacksonville, United States
- Coeur d'Alene, United States
- Chicago, United States
- Lake Charles, United States
- Shreveport, United States
- Las Vegas, United States
- Cincinnati, United States
- Cleveland, United States
- Oklahoma City, United States
- Antwerp, Belgium
- Sofia, Bulgaria
- Tallinn, Estonia
- Tartu, Estonia
- Viljandi, Estonia
- Hus, Finland
- Kellokoski, Finland
- Chennai, India
- Hyderabad, India
- Mangalore, India
- Varanasi, India
- Gdansk, Poland
- Lódź, Poland
- Poznan, Poland
- Sosnowiec, Poland
- Torun, Poland
- Warsaw, Poland
- Bucharest, Romania
- Ekaterinburg Na, Russia
- Kazan', Russia
- Moscow, Russia
- Moscow Russia, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Smolensk Region N/A, Russia
- Stavropol Na, Russia
- Tomsk Na, Russia
- Yaroslavl, Russia
- Cheonan, South Korea
- Gyeonggi-do, South Korea
- Kyunggi-Do, South Korea
- Seoul, South Korea
- Dnipro, Ukraine
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Paliperidone ER, tracking side effects to assess safety and tolerability in young people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone ER.
Who was this study for?
Listed age limits: 12 years to 17 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia